Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:
“NLST post hoc:
- LCS-eligible ever-smokers (n=31,560),
- LDCT vs CXR: LC death HR 0.88; all-cause 0.98 (NS),
- Quit ≤2 yr vs smoking (CXR arm): LC death HR 0.62, all-cause 0.68.
Who pays for cessation in LCS?”
Title: Low-dose CT Screening and Smoking Cessation: Separate and Joint Associations with Mortality among Ever-Smokers Eligible for Lung Cancer Screening.
Authors: Huan Wang, Clara Frick, Sha Sha, Dominic Edelmann, Megha Bhardwaj, Hermann Brenner.
Full article in the Journal of Thoracic Oncology.

You can also read: BioMILD at Nearly 10 Years: Risk-Adapted LDCT Screening Sustains Early Lung Cancer Detection With Extended Intervals.
